StreetInsider.com News Articles

Form 4 Taysha Gene Therapies, For: Jun 01 Filed by: Stalfort John A III

Tue, 02 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260602/26592234.html

Form 4 Taysha Gene Therapies, For: Jun 01 Filed by: Stalfort John A III

Tue, 02 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260602/26592234.html

Form 4 Taysha Gene Therapies, For: Jun 01 Filed by: Donenberg Phillip B.

Tue, 02 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26592218.html

Form 4 Taysha Gene Therapies, For: Jun 01 Filed by: Donenberg Phillip B.

Tue, 02 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26592218.html

Form 4 Taysha Gene Therapies, For: Jun 01 Filed by: Long Alison S

Tue, 02 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26592223.html

Form 4 Taysha Gene Therapies, For: Jun 01 Filed by: Long Alison S

Tue, 02 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26592223.html

Form 4 Taysha Gene Therapies, For: Jun 01 Filed by: Sepp-Lorenzino Laura

Tue, 02 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26592230.html

Form 4 Taysha Gene Therapies, For: Jun 01 Filed by: Sepp-Lorenzino Laura

Tue, 02 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26592230.html

Form 8-K Taysha Gene Therapies, For: Jun 01

Tue, 02 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26591576.html

Form 8-K Taysha Gene Therapies, For: Jun 01

Tue, 02 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26591576.html

Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: Vestal Point Capital, LP

Fri, 15 May 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260515/26507810.html

Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: Vestal Point Capital, LP

Fri, 15 May 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260515/26507810.html

Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RTW INVESTMENTS, LP

Fri, 15 May 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260515/26500183.html

Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RTW INVESTMENTS, LP

Fri, 15 May 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260515/26500183.html

Taysha Gene Therapies (TSHA) PT Raised to $10 at BMO Capital

Thu, 07 May 2026 07:46:52 -0400

BMO Capital analyst Evan Seigerman raised the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $10.00 (from $8.00) while maintaining a Outperform rating.

Form 10-Q Taysha Gene Therapies, For: Mar 31

Wed, 06 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260506/26439865.html

Form 10-Q Taysha Gene Therapies, For: Mar 31

Wed, 06 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260506/26439865.html

Form 8-K Taysha Gene Therapies, For: May 06

Wed, 06 May 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260506/26439624.html

Form 8-K Taysha Gene Therapies, For: May 06

Wed, 06 May 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260506/26439624.html

Taysha Gene Therapies (TSHA) Misses Q1 EPS by 2c

Wed, 06 May 2026 08:03:21 -0400

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($0.12), $0.02 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 06 May 2026 08:00:00 -0400

Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent breakthrough therapy Type B meeting

Further advanced dosing in the REVEAL pivotal trial, with enrollment in the ASPIRE

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 06 May 2026 08:00:00 -0400

Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent breakthrough therapy Type B meeting

Further advanced dosing in the REVEAL pivotal trial, with enrollment in the ASPIRE

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 06 May 2026 08:00:00 -0400

Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent breakthrough therapy Type B meeting

Further advanced dosing in the REVEAL pivotal trial, with enrollment in the ASPIRE

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 06 May 2026 08:00:00 -0400

Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent breakthrough therapy Type B meeting

Further advanced dosing in the REVEAL pivotal trial, with enrollment in the ASPIRE

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 06 May 2026 08:00:00 -0400

Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent breakthrough therapy Type B meeting

Further advanced dosing in the REVEAL pivotal trial, with enrollment in the ASPIRE